Overcoming the Intrinsic Gefitinib-resistance via Downregulation of AXL in Non-small Cell Lung Cancer

BACKGROUND: Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, is a limited factor in the treatment of non-small-cell lung cancer (NSCLC) patients. Therefore, ongoing studies are trying to identify EGFR-TKIs-resistant mechanisms and to discover...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cancer Prev
Main Authors: Jeong, Inae, Song, Jayoung, Bae, Song Yi, Lee, Sang Kook
Formato: Artigo
Idioma:Inglês
Publicado em: Korean Society of Cancer Prevention 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6951316/
https://ncbi.nlm.nih.gov/pubmed/31950021
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15430/JCP.2019.24.4.217
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados